دورية أكاديمية
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
| العنوان: | Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. |
|---|---|
| المؤلفون: | Burger DM; Department of Clinical Pharmacy, University Medical Center, Nijmegen, The Netherlands. D.Burger@klinfarm.azn.nl, Hugen PW, Aarnoutse RE, Hoetelmans RM, Jambroes M, Nieuwkerk PT, Schreij G, Schneider MM, van der Ende ME, Lange JM |
| مؤلفون مشاركون: | ATHENA Study Group |
| المصدر: | Therapeutic drug monitoring [Ther Drug Monit] 2003 Feb; Vol. 25 (1), pp. 73-80. |
| نوع المنشور: | Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print Cited Medium: Print ISSN: 0163-4356 (Print) Linking ISSN: 01634356 NLM ISO Abbreviation: Ther Drug Monit Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: [New York] Raven Press. |
| مواضيع طبية MeSH: | HIV Infections/*blood , HIV Infections/*drug therapy , Nelfinavir/*blood , Nelfinavir/*therapeutic use, Adult ; Antiretroviral Therapy, Highly Active/methods ; Antiretroviral Therapy, Highly Active/statistics & numerical data ; Area Under Curve ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Statistics, Nonparametric ; Treatment Failure |
| مستخلص: | The relationship between plasma concentrations of nelfinavir and virologic treatment failure was investigated to determine the minimum effective concentration of nelfinavir. Plasma samples were prospectively collected from treatment-naive patients who began taking nelfinavir, 1,250 mg BID + two nucleoside reverse transcription inhibitors (NRTIs). Nelfinavir concentration ratios were calculated by dividing each individual nelfinavir level by the time-adjusted population value. Virologic failure was defined as either no response (a detectable viral load after 6 months) or a relapse (detectable viral load after being undetectable, or an increase in viral load >1 log above nadir). Forty-eight patients were included with a median follow-up period of 8 months. The median concentration ratio of nelfinavir was 0.98 (interquartile range, 0.76-1.47). Virologic failure was observed in 29% of the patients. In a univariate analysis, the nelfinavir concentration ratio appeared to be the single determinant that was related to virologic failure (P = 0.039). Patients with a median ratio <0.90 had a relative risk of 3.0 (95% CI, 1.2-7.6) for virologic failure. Using this threshold, virologic failures were detected with 64% sensitivity and 74% specificity (P = 0.014). Virologic failure of nelfinavir-containing triple therapy can be explained, to a large extent, by low plasma levels of nelfinavir. |
| المشرفين على المادة: | HO3OGH5D7I (Nelfinavir) |
| تواريخ الأحداث: | Date Created: 20030128 Date Completed: 20030709 Latest Revision: 20190906 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1097/00007691-200302000-00011 |
| PMID: | 12548148 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0163-4356 |
|---|---|
| DOI: | 10.1097/00007691-200302000-00011 |